Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program; Human Abuse Potential Study Dosing Complete; Phase 2b CORAL Trial In Idiopathic Pulmonary Fibrosis Chronic Cough Reaches 50% Enrollment Milestone; Sample Size Re-Estimation Results Expected In December 2024
Portfolio Pulse from Benzinga Newsdesk
Trevi Therapeutics announced updates on its clinical development program for Haduvio, an investigational therapy for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The Phase 2b CORAL trial has reached a 50% enrollment milestone, with sample size re-estimation results expected in December 2024. Additionally, the Human Abuse Potential study dosing is complete, with topline results also expected in December 2024.
October 03, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trevi Therapeutics has reached significant milestones in its clinical trials for Haduvio, with 50% enrollment in the Phase 2b CORAL trial and completion of dosing in the Human Abuse Potential study. Results are anticipated in December 2024.
The completion of significant milestones in Trevi's clinical trials for Haduvio suggests progress in their development pipeline, which could positively impact investor sentiment and the stock price. The anticipation of results in December 2024 provides a timeline for potential future developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100